Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients

Angiogenesis is an essential process for the expansion of multiple myeloma (MM), in which many angiogenic factors participate. Endoglin (CD105) is a transforming growth factor‐β co‐receptor, being mainly expressed in angiogenic endothelial cells and has been used as a marker of tumor angiogenesis, h...

Full description

Saved in:
Bibliographic Details
Published in:Hematological oncology 2013-12, Vol.31 (4), p.201-205
Main Authors: Pappa, CA, Alexandrakis, MG, Boula, A, Psarakis, FE, Kolovou, A, Bantouna, V, Stavroulaki, E, Tsirakis, G
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
angiogenesis
Antigens, CD - blood
Antigens, CD - physiology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone Marrow - pathology
cytokines
Disease Progression
Endoglin
Female
Humans
Interleukin-18 - blood
Kaplan-Meier Estimate
Male
Middle Aged
multiple myeloma
Multiple Myeloma - blood
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Multiple Myeloma - physiopathology
Neoplasm Proteins - blood
Neovascularization, Pathologic - physiopathology
Prognosis
Receptors, Cell Surface - blood
Receptors, Cell Surface - physiology
Ribonuclease, Pancreatic - blood
Vascular Endothelial Growth Factor A - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiogenesis is an essential process for the expansion of multiple myeloma (MM), in which many angiogenic factors participate. Endoglin (CD105) is a transforming growth factor‐β co‐receptor, being mainly expressed in angiogenic endothelial cells and has been used as a marker of tumor angiogenesis, having prognostic potential. The aim of the study was to evaluate serum levels of soluble CD105 (sCD105) in MM patients, both during diagnosis and after effective conventional chemotherapy, in the plateau phase, and to correlate them with the clinical stage of the disease, as well as with the known angiogenic factors vascular endothelial growth factor, angiogenin and interleukin‐18 (IL‐18). Serum levels of the aforementioned factors were measured, by enzyme‐linked immunosorbent assay, in 56 newly diagnosed MM patients, in 35 of them who entered plateau phase and in 24 healthy controls. Bone marrow aspirations were also performed in all patients to determine plasma cell infiltration. All measured cytokines were higher in MM patients compared with controls and with advancing disease stage (p 
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.2044